Does taking aflibercept every 8 weeks keep vision gains in diabetic macular edema?
Aflibercept is an anti-VEGF injection used to treat diabetic macular edema (DME), a leading cause of vision loss in people with diabetes. The standard dosing schedule is one injection every 4 weeks initially, then every 8 weeks for maintenance. Research shows that the every-8-week regimen effectively sustains the vision improvements gained during the initial monthly loading doses.
What the research says
A large phase 2/3 trial called PHOTON followed patients with DME for 96 weeks. Those who received aflibercept 2 mg every 8 weeks (after monthly loading doses) maintained an average gain of about 8.8 letters on the eye chart from the start of the study 3. This was comparable to the vision gains seen with a newer higher-dose formulation (8 mg) given every 12 or 16 weeks 3. The study confirms that the standard 2 mg every 8 weeks schedule keeps vision stable over nearly two years.
Other studies support the effectiveness of aflibercept for DME. A systematic review of biosimilar versions found they match the original drug in improving vision and reducing retinal swelling 4. The FDA has approved aflibercept (brand names Eylea, Eylea HD, and Pavblu) specifically for DME 28. While some research explores newer delivery methods or different drugs, the every-8-week aflibercept regimen remains a well-established option for maintaining vision gains 16.
What to ask your doctor
- Is aflibercept 2 mg every 8 weeks a good option for maintaining my vision gains?
- How often will I need eye exams or imaging to monitor my DME?
- Are there any newer treatments (like higher-dose aflibercept or other drugs) that might work better for me?
- What should I do if I miss an injection appointment?
- What side effects should I watch for between injections?
This question is drawn from common patient questions about this topic and answered using cited medical research. We do not provide individualized advice.